Clinical trials: Thymus Cancer
Thymic Carcinoma, Thymus Neoplasms
Pembrolizumab and Epacadostat in Patients With Thymic Carcinoma
This is a non-randomized clinical trial in patients with thymic carcinomas who failed prior systemic therapy. All subjects will receive pembrolizumab and epacadostat treatment in three week cycles until unacceptable toxicity…
- Conditions
- Thymic Carcinoma, Thymus Neoplasms, Thymus Cancer
- Trial name
- NCT02364076
- Testing
- Pembrolizumab, Epacadostat
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- Georgetown University
Thymoma, Thymus Cancer
A Phase 2 Study of Amrubicin in Relapsed or Refractory Thymic Malignancies
A research study of the drug amrubicin in patients with cancer of the thymus (thymoma or thymic carcinoma). We hope to learn whether this drug is an effective and safe treatment for thymic cancers.
- Conditions
- Thymoma, Thymus Cancer, Thymic Carcinoma
- Trial name
- NCT01364727
- Testing
- Amrubicin
- Where
- 2 sites in United States
- Volunteers
- 33 people
- Sponsor
- Heather Wakelee
Carcinoma, Non-Small-Cell Lung, Thymus Neoplasms
18F FLT Imaging Studies of Treatment Response for Lung Cancer and Thymoma
Background: Imaging studies like positron emission tomography (PET) and computed tomography (CT) scans are used to detect tumor responses to cancer treatment.
- Trial name
- NCT01610544
- Testing
- 3'-deoxy-3'-18F fluorothymidine (FLT), PET/CT scan
- Sponsor
- National Cancer Institute (NCI)
Thymoma, Thymic Carcinoma
A Phase 1/2 Study of PXD101 (Belinostat) in Combination With Cisplatin, Doxorubicin and Cyclophosphamide in the First Line Treatment of Advanced or Recurrent Thymic, Malignancies
Background: Tumors of the thymus are rare and can be treated with surgery, but it is often difficult to determine whether a thymic tumor is malignant based on biopsy alone and the long-term survival rate is less than 50 percent.
- Trial name
- NCT01100944
- Testing
- PXD101with cisplatin+doxorubicin+cyclophosphamide
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- National Cancer Institute (NCI)
Thymic Cancer
A Phase II Study of Palbociclib for Recurrent or Refractory Advanced Thymic Epithelial Tumor
This is a phase II single center, open-label, single arm study of palbociclib treatment in patients with recurrent or metastatic advanced TETs after failure of one or more cytotoxic chemotherapy regimens.
- Trial name
- NCT03219554
- Testing
- Palbociclib
- Where
- South Korea
- Volunteers
- 33 people
- Sponsor
- Samsung Medical Center
Pancreatic Cancer, Thymic Cancer
Genetic Evaluation of Families With Endocrine Cancers
This study is being conducted to identify altered genetic factors that may exist and influence endocrine cancers in unrelated MEN1 families with different cancers.
- Conditions
- Pancreatic Cancer, Thymic Cancer, Parathyroid Disease, MEN1 Syndrome
- Trial name
- MEN1 (NCT01794676)
- Testing
- Blood draw
- Where
- United States
- Volunteers
- 9 people, healthy volunteers welcome
- Sponsor
- Jersey Shore University Medical Center
Thymoma, Thymic Tumor
Prospective Study of Stereotactic Body Radiation Therapy for Thymoma Inoma: Therapeutic Effect and Toxicity Assessment
For patients with unresectable or recurrent disease, radiation is routinely administered, often in combination with systemic chemotherapy.
- Trial name
- NCT03078699
- Testing
- stereotactic body radiation therapy
- Where
- China
- Volunteers
- 32 people
- Sponsor
- Third Military Medical University
Lung Cancer, Prostate Cancer
Cognitive Testing of Tobacco Use Measurement Items for Administration With Cancer Patients and Survivors
Background: People who have cancer have more medical problems if they smoke. Some studies show that smoking even makes cancer treatment less effective.
- Conditions
- Lung Cancer, Prostate Cancer, Bladder Cancer, Thymic Cancer
- Trial name
- NCT02233842
- Testing
- Participant interview
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- National Cancer Institute (NCI)
Locally Advanced Stage III or IV Thymic Cancer
Neoadjuvant Chemotherapy for Locally Advanced Thymic Cancer
We try to evaluate whether neoadjuvant docetaxel plus cisplatin can increase the complete resection rate in advanced thymic carcinoma.
- Trial name
- NCT01312324
- Testing
- neoadjuvant docetaxel/cisplatin
- Where
- South Korea
- Volunteers
- 27 people
- Sponsor
- Samsung Medical Center
Carcinomas, Amyloidosis
B-Receptor Signaling in Cardiomyopathy
We hope to determine the importance of different genes (including B receptors) in anthracycline-induced cardiomyopathy. This has important benefits to patients exposed to anthracyclines, as this could help determine whether…
- Conditions
- Carcinomas, Amyloidosis, Anal Cancer, Anemia
- Trial name
- NCT01135849
- Where
- United States
- Volunteers
- 99 people
- Sponsor
- Daniel Bernstein
Pleural Metastases, Breast Cancer
Heated Chemotherapy for Cancers That Have Spread to the Chest Cavity
Cancers that have spread to the inner lining of the chest are classified as Stage IV and bear a poor prognosis. Surgery is rarely an option, with palliative chemotherapy and/or radiation therapy the only treatment options.
- Conditions
- Pleural Metastases, Breast Cancer, Colon Cancer, Ovarian Cancer
- Trial name
- NCT01163552
- Testing
- Surgical debulking and Intrathoracic Hyperthermic Chemotherapy
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- St. Luke's-Roosevelt Hospital Center
Thymic Cancer, Thymoma
A Study to Test the Safety and Efficacy of Erlotinib Plus Bevacizumab to Treat Advanced Thymoma and Thymic Cancer
The purpose of this study is to determine the rate of response with the combination of erlotinib and bevacizumab in previously treated patients with thymoma or thymic carcinoma, and to determine potential molecular markers that…
- Trial name
- NCT00369889
- Testing
- bevacizumab, Erlotinib
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Indiana University
Respiratory Tract Neoplasms, Thymic Neoplasms
High Dose Somatostatin Analogues in Neuroendocrine Tumors
Octreotide (OCT) is a somatostatin analogue (SSA) available in a long-acting formulation, conventionally administered every 28 days at the maximum dose of 30 mg.
- Conditions
- Respiratory Tract Neoplasms, Thymic Neoplasms, Pancreatic Neoplasms, Gastrointestinal Neoplasms
- Trial name
- HIDONET (NCT00990535)
- Testing
- Octreotide-LAR
- Where
- Italy
- Volunteers
- 28 people
- Sponsor
- Federico II University